SARCOMA

Brian Van Tine, MD, PhD, assistant professor, Washington University School of Medicine, discusses the development of olaratumab (Lartruvo) in soft tissue sarcoma.

Although the addition of pazopanib (Votrient) to gemcitabine in the second-line treatment of patients with metastatic or relapsed uterine or soft tissue leiomyosarcomas demonstrated disease control in the majority of patients, statistical endpoints were not met in the phase II UNICANCER SARCOMA 11 study, according to results reported at the 2017 ESMO Congress.

CMB305, an immunotherapy regimen that generates and expands anti-NY-ESO-1 T cells, demonstrated a favorable survival rate in patients with recurrent soft tissue sarcoma, compared with other agents approved for the disease.

Lisa H. Butterfield, PhD, professor of medicine, surgery, and immunology, director, University of Pittsburgh Immunologic Monitoring and Cellular Products Laboratory, and president of the Society for Immunotherapy of Cancer, discusses the SARC028 study, which explored the efficacy of pembrolizumab (Keytruda) in advanced soft tissue and bone sarcomas.

Patients with intermediate- or high-risk gastrointestinal stromal tumors were less likely to experience recurrence after 5 years of treatment with imatinib, according to results from the phase II PERSIST-5 trial.

Jonathan C. Trent, MD, PhD, recently discussed the treatment considerations he makes when treating patients with gastrointestinal stromal tumors (GIST). Trent discussed his treatment decisions based on 2 case scenarios during a&nbsp;<em>Targeted Oncology</em>&nbsp;live case-based peer perspectives dinner.

There are more than 70 subtypes that fall under the soft tissue sarcoma (STS) umbrella, according to the World Health Organization, and only account for approximately 1% of all cancers in adult patients.&nbsp;Yet, physicians continue to try to treat all sarcomas the same, making drug development for these types of tumors quite slow and frustrating.

A look back at all the FDA news that happened in the month of June, including in multiple myeloma, hematology, sarcoma, and lung cancer.

The FDA has granted orphan drug designation to its EZH2-inhibitor tazemetostat for the treatment of adults with INI1-negative epithelioid sarcoma,&nbsp;Epizyme has announced.

Six to 9 months of treatment with neoadjuvant imatinib (Gleevec) was a promising treatment for patients with large gastric gastrointestinal stromal tumors (GIST), according to the results of a small multinational study in Asian patients.

Lisa H. Butterfield, PhD, discusses efficacy and biomarker results of the phase II SARC028 study, which explored pembrolizumab (Keytruda) in advanced soft tissue and bone sarcomas, during the 2017 ASCO Annual Meeting.

Researchers at Dana-Farber Cancer Institute have identified an exceptional responder to pembrolizumab &ndash; a treatment-na&iuml;ve patient with metastatic uterine leiomyosarcoma who had a complete tumor remission for more than 2 years on the PD-1 inhibitor.

Survivors of Ewing sarcoma are left with few long-term complications, according to results from a nonrandomized observational cohort study.

Researchers offer a review of the role of adjuvant or neoadjuvant chemotherapy, targeted therapy, and immunotherapy in localized soft tissue sarcoma.&nbsp;

The investigational compound 5-imino-13-deoxydoxorubicin showed promising activity in patients with metastatic and nonresectable soft tissue sarcoma.

Shreyaskumar R. Patel, MD and Jonathan C. Trent, MD discussed the use of trabectedin and the future of the treatment paradigms in soft tissue sarcoma.

This section covers the Current Treatment Strategies section of the current Evolving Paradigms in Soft Tissue Sarcoma issue.

External beam radiation therapy (EBRT) lowers the risk of local recurrence in patients with either retroperitoneal or extremity sarcomas.

This section covers the Emerging Cytotoxic Agents, Current and Emerging Targets, and Emerging Therapies for Specific Histologies sections of the current Evolving Paradigms in Soft Tissue Sarcoma issue.

This section covers the Current Treatment Strategies section of the current Evolving Paradigms in Soft Tissue Sarcoma issue.

This section covers the Introduction and Epidemiology, Risk Factors, Detection and Diagnosis, and Staging and Prognosis sections of the current Evolving Paradigms in Soft Tissue Sarcoma issue.

Several subtypes of difficult-to-treat sarcomas may respond to treatment with PD-1 pathway inhibiting immunotherapies, according to findings of an immunohistochemistry analysis of a large patient population.

Sarcoma physician and researcher Robert G. Maki, MD, PhD, has joined the leadership team at Northwell Health Cancer Institute.

Elizabeth Loggers, MD, PhD, discusses the findings of the phase II SARC028 trial in sarcoma.

Nancy Gordon, MD, speaks about her osteosarcoma research, the next steps following the findings of the study, and what she envisions for the treatment landscape of osteosarcoma over the next decade.